Skip to Content
Merck
All Photos(1)

Key Documents

GW20070F

Sigma-Aldrich

Anti-APOB antibody produced in chicken

affinity isolated antibody, buffered aqueous solution

Synonym(s):

Anti-Apolipoprotein B, Anti-Apolipoprotein B-100

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
12352203
NACRES:
NA.41

biological source

chicken

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

species reactivity

human

manufacturer/tradename

Genway 15-288-20070F

technique(s)

indirect ELISA: suitable
western blot: suitable

NCBI accession no.

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... APOB(338)

Immunogen

Apolipoprotein B-100 native protein.
Immunogen Sequence: GI # 4502153, sequence 1-4563

Application

Anti-APOB antibody produced in chicken is suitable for indirect ELISA and western blotting analysis at a dilution of 1:500, for tissue or cell staining at a dilution of 1:200. It may also be used for serum lipid analyses and apolipoprotein assays.

Biochem/physiol Actions

Apolipoprotein B (apoB) is the main protein component of triacylglyceride (TAG)-rich lipoproteins. It includes chylomicrons as well as very low density lipoprotein (the "bad cholesterol"). The N-terminal domains of apoB support the intrinsic capability of co-translational lipid recruitment. Apolipoprotein B is considered as a key structural component of all the atherogenic lipoproteins and its genetic variation may affect plasma ApoB and lipid levels, which may influence atherogenesis.

Physical form

Solution in phosphate buffered saline containing 0.02% sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jovana Nikolajevic Starcevic et al.
VASA. Zeitschrift fur Gefasskrankheiten, 43(3), 171-180 (2014-05-07)
Apolipoprotein B is a key structural component of all the atherogenic lipoproteins (LDL, VLDL and IDL). Genetic variations of the ApoB gene may affect plasma ApoB and lipid levels, thus influencing atherogenesis. The present study was designed to investigate the
A A Qureshi et al.
The Journal of nutrition, 131(2), 223-230 (2001-02-13)
A tocotrienol-rich fraction (TRF(25)) and novel tocotrienols (d-P(21)-T3 and d-P(25)-T3) of rice bran significantly lowered serum and low density lipoprotein cholesterol levels in chickens. The present study evaluated the effects of novel tocotrienols on lipid metabolism in swine expressing hereditary
Matthew A Mitsche et al.
The Journal of biological chemistry, 289(13), 9000-9012 (2014-02-12)
Apolipoprotein B (apoB) is the principal protein component of triacylglyceride (TAG)-rich lipoproteins, including chylomicrons and very low density lipoprotein, which is the precursor to LDL (the "bad cholesterol"). TAG-rich lipoprotein assembly is initiated by the N-terminal βα1 superdomain of apoB
M B Elam et al.
Arteriosclerosis, thrombosis, and vascular biology, 18(12), 1942-1947 (1998-12-16)
Cilostazol is an antiplatelet agent and vasodilator marketed in Japan for treatment of ischemic symptoms of peripheral vascular disease. It is currently being evaluated in the United States for treatment of symptomatic intermittent claudication (IC). Cilostazol has been shown to

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service